Perspective Therapeutics (NYSEAMERICAN:CATX) CEO Johan Spoor Buys 47,000 Shares of Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) CEO Johan Spoor acquired 47,000 shares of Perspective Therapeutics stock in a transaction dated Wednesday, November 11th. The shares were acquired at an average price of $0.81 per share, with a total value of $38,070.00. Following the completion of the transaction, the chief executive officer owned 106,383 shares of the company’s stock, valued at approximately $86,170.23. This trade represents a 79.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $0.83 on Thursday. Perspective Therapeutics, Inc. has a 12-month low of $0.78 and a 12-month high of $6.16. The business has a 50 day simple moving average of $2.20 and a 200 day simple moving average of $3.46. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 6.61.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. Sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -0.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Royal Bank Of Canada lowered shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $14.00 to $4.00 in a research report on Monday, October 26th. BMO Capital Markets reissued an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Bank of America dropped their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Finally, William Blair initiated coverage on shares of Perspective Therapeutics in a research note on Friday, September 18th. They issued an “outperform” rating for the company. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Perspective Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $10.10.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CATX. Commodore Capital LP acquired a new stake in Perspective Therapeutics in the 1st quarter valued at about $26,424,000. Affinity Asset Advisors LLC boosted its position in shares of Perspective Therapeutics by 954.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after purchasing an additional 2,864,582 shares in the last quarter. Avidity Partners Management LP boosted its position in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares in the last quarter. Spruce Street Capital LP acquired a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $10,955,000. Finally, Yu Fan acquired a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $4,401,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.